We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Novozymes Biopharma Announces new Study Data Using Recombumin in Protein Drug Formulation
News

Novozymes Biopharma Announces new Study Data Using Recombumin in Protein Drug Formulation

Novozymes Biopharma Announces new Study Data Using Recombumin in Protein Drug Formulation
News

Novozymes Biopharma Announces new Study Data Using Recombumin in Protein Drug Formulation

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Novozymes Biopharma Announces new Study Data Using Recombumin in Protein Drug Formulation"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Novozymes Biopharma announces new data which demonstrates extended shelf life of protein drug products using Recombumin, recombinant human albumin.

The data, presented for the first time at a recent protein-focused industry event, reveals the potential for Recombumin to reduce product loss by preventing the physical and chemical degradation of protein drugs.

A data sheet entitled "Recombumin®: A pharmaceutical excipient in the stabilization of therapeutic protein products" details the findings.

The study investigated the ability of Recombumin, a recombinant human albumin expressed in Saccharomyces cerevisiae, to prevent the deterioration of protein drug products in a variety of test formulations.

The study particularly addressed Recombumin's minimization of surface adsorption, oxidation and aggregation in comparison to excipients commonly used for the purpose of formulating protein drugs.

The new data demonstrates that Recombumin has the capacity to improve the shelf life of protein drug products. The study's findings indicate that Recombumin performed as well as and often better than the comparators making it an effective multi-purpose excipient with the capability to reduce the total number of excipients required and therefore simplifying the formulation strategy.
Advertisement